Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 127 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter

  1. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA178

  2. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    25 July 2018
    View recommendations

    Sections for TA533

  3. Are there subgroups of people with Graves' disease who have a particularly good response to antithyroid drugs?

    long-term outcomes than antithyroid drugs in terms of thyroid status, but with a greater risk of thyroid eye disease. There...

    Research recommendation
    Published
    10 February 2020

  4. Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who have had surgery and radioactive iodine (RAI), what is the optimal duration of thyroid stimulating hormone suppression?

    NG230/04 Question Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who...

    Research recommendation
    Published
    6 January 2023

  5. Imaging for further staging: For people with differentiated thyroid cancer who have initial ultrasound evidence of extensive local spread (T2N1), what is the clinical and cost effectiveness of CT, MRI or F-18 FDG PET-CT scanning, with or without ultrasound, as part of a further staging strategy?

    Question Imaging for further staging: For people with differentiated thyroid cancer who have initial ultrasound evidence of extensive...

    Research recommendation
    Published
    6 January 2023

  6. Thyroid peroxidase antibody testing: For people with indeterminate cytopathology, what is the clinical and cost effectiveness of thyroid peroxidase antibody testing?

    Question Thyroid peroxidase antibody testing: For people with indeterminate cytopathology, what is the clinical and cost effectiveness...

    Research recommendation
    Published
    6 January 2023

  7. Active surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness of active surveillance compared with surgery?

    surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness...

    Research recommendation
    Published
    6 January 2023

  8. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  9. Duration of follow up: What is the clinical and cost effectiveness for different durations of follow up for people with differentiated thyroid cancer who have been treated?

    effectiveness for different durations of follow up for people with differentiated thyroid cancer who have been treated? Any explanatory...

    Research recommendation
    Published
    6 January 2023

  10. External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer?

    effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    6 January 2023

  11. Radioactive iodine: What is the clinical and cost effectiveness of RAI after total or completion thyroidectomy for people with T2 disease and no adverse pathological features?

    the clinical and cost effectiveness of RAI after total or completion thyroidectomy for people with T2 disease and no adverse...

    Research recommendation
    Published
    6 January 2023

  12. Molecular tests: In fine-needle aspiration cytology (FNAC) samples that are adequate but cannot differentiate between benign and malignant samples, what is the clinical and cost effectiveness of molecular testing for thyroid cancer?

    samples, what is the clinical and cost effectiveness of molecular testing for thyroid cancer? Any explanatory notes(if applicable) For a...

    Research recommendation
    Published
    6 January 2023

  13. What is the clinical and cost effectiveness of percutaneous thermal ablation for benign thyroid nodules?

    for benign thyroid nodules? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...

    Research recommendation
    Published
    10 February 2020

  14. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

    Technology appraisal guidance
    Last updated
    27 November 2013
    View recommendations

    Sections for TA75

  15. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

    Technology appraisal guidance
    Published
    27 May 2020
    View recommendations

    Sections for TA630